Pharmafile Logo
Pharmafocus logo
Advanced Search

AbbVie

Showing 15 posts of 220 posts found.

abbviehqe_004_low

AbbVie turns to tau for Alzheimer’s in $1.1bn deal

February 21, 2018
Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …

News
abbvieuse_036_low

Death in trial blackens AbbVie’s positive rheumatoid arthritis data

December 21, 2017
Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis

AbbVie posted strong results from its Phase 3 trial into its treatment for rheumatoid arthritis, upadacitinib, but discussions of the …

News

AbbVie posts strong psoriasis data but can it stand out from crowd?

December 5, 2017
Manufacturing and Production, Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical

AbbVie revealed that its IL-23 inhibitor, risankizumab, had successfully met all of its endpoints in a Phase 3 trials into …

News
abbvieuse_054_low

AbbVie’s psoriasis drug smashes all endpoints

October 26, 2017
Medical Communications, Research and Development AbbVie, IL-23, biotech, drugs, pharma, pharmaceutical, risankizumab

AbbVie already know well what it’s like to have a lead candidate in the psoriasis field, after having Humira sat …

News
androgel

AbbVie hit with $140m fine over fraudulent marketing of Androgel

October 6, 2017
Medical Communications, Sales and Marketing AbbVie, androgel, biotech, drugs, pharma, pharmaceutical

AbbVie has been stung with a $140 million damages award to a man that suffered a heart attack after using …

News
abbvie_0

AbbVie adds biologic production capability to Singapore facility

October 4, 2017
Manufacturing and Production, Research and Development AbbVie, Singapore, biologics, pharma, pharmaceuticals

AbbVie has expanded the operational capability of its facility located at the Tuas Biomedical Park in Singapore with the addition …

News
humira_abbott_

Five more biosimilar-free years for AbbVie’s megablockbuster

September 28, 2017
Medical Communications, Sales and Marketing AbbVie, Amgen, Amjevita, Humira, biotech, drugs, pharma, pharmaceutical

Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the …

News
acute_leukemia-all

Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint

September 19, 2017
Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical

Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …

News
sandoz

Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data

September 15, 2017
Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical

Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …

News

Questions raised after two deaths in AbbVie arthritis study

September 12, 2017
Manufacturing and Production, Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis

AbbVie’s rheumatoid arthritis drug, upadacitinib, is the company’s big plan to manage the inevitable loss of sales from Humira, as …

News
sanofi_regeneron

New potential blockbuster RA treatment enters European market

June 27, 2017
Sales and Marketing AbbVie, Humria, Kevzara, Regeneron, Sanofi

The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the …

News
abbvieuse_036_low

AbbVie loses $15 million Depakote birth-defect case

June 12, 2017
Sales and Marketing AbbVie, Abbott, Depakote

Court cases for the anti-seizure medicine Depakote continue to rumble on for AbbVie, with the latest case finding AbbVie liable …

News

AbbVie posts promising data on RA drug

June 8, 2017
Research and Development AbbVie, JAK inhibitor

AbbVie posted results on upadacitinib, the latest drug in its pipeline for rheumatoid arthritis (RA) and the results have given …

News
abbvie_uk_france

Abbvie names new General Managers for UK and France

June 2, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, appointment

Abbvie has announced a double appointment across its UK and French operations, naming Jérôme Bouyer as its UK General Manager, …

Appointment
abbviehqe_011_low

AbbVie suffers knock to Humira patent

May 19, 2017
Medical Communications, Sales and Marketing AbbVie, Humira, patents

Humira is the largest selling pharmaceutical drug in the world. The treatment for rheumatoid arthritis brought in over $16 billion …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023